An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab
Sponsor: Hoffmann-La Roche